Drreddys Laboratories | RDY - Operating Profit


Drreddys Laboratories reported INR829M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
ANI Pharmaceuticals USD 38.71M 9.58M Mar/2026
Aurora Cannabis CAD -10.03M 25.76M Mar/2026
Bayer EUR 3.53B 2.42B Mar/2026
Canopy Growth CAD -27.47M 14.81M Mar/2026
Cipla INR 6.14B 3.63B Mar/2026
Corcept Therapeutics USD -49.6M 54.09M Mar/2026
Drreddys Laboratories INR 829M 13.5B Mar/2026
GlaxoSmithKline GBP 2.29B 856M Mar/2026
Hikma Pharmaceutical USD 348M 161M Dec/2025
Lonza CHF 673M 243M Jun/2025
Novartis USD 4.24B 171M Mar/2026
Pacira USD 4.62M 1.43M Mar/2026
Phibro Animal Health USD 54.99M 2.36M Dec/2025
Prestige Brands USD 75.49M 7M Mar/2026
Richter Gedeon HUF 62.32B 1.26B Mar/2026
Sun Pharmaceuticals INR 40.62B 6.95B Dec/2025
Supernus Pharmaceuticals USD -35.25M 49.07M Mar/2026
Teva Pharmaceutical Industries USD 758M 271M Mar/2026